HC Wainwright Estimates OmniAb’s Q2 Earnings (NASDAQ:OABI)

OmniAb, Inc. (NASDAQ:OABI) – HC Wainwright issued their Q2 2026 earnings estimates for OmniAb in a research report issued on Thursday, March 5th. HC Wainwright analyst J. Pantginis anticipates that the company will post earnings of ($0.09) per share for the quarter. The consensus estimate for OmniAb’s current full-year earnings is ($0.61) per share. HC Wainwright also issued estimates for OmniAb’s Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at ($0.08) EPS and FY2030 earnings at $0.00 EPS.

OmniAb (NASDAQ:OABI) last posted its earnings results on Wednesday, March 4th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.03). OmniAb had a negative net margin of 347.04% and a negative return on equity of 23.90%. The business had revenue of $8.38 million for the quarter, compared to analyst estimates of $9.00 million.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of OmniAb in a report on Monday, December 22nd. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $6.67.

OmniAb Price Performance

NASDAQ OABI opened at $2.00 on Friday. The company has a market capitalization of $287.92 million, a price-to-earnings ratio of -3.51 and a beta of 0.13. OmniAb has a 12 month low of $1.22 and a 12 month high of $3.46. The company’s fifty day moving average price is $1.83 and its two-hundred day moving average price is $1.75.

Insider Buying and Selling

In other OmniAb news, CFO Kurt A. Gustafson sold 23,922 shares of the stock in a transaction on Monday, December 8th. The stock was sold at an average price of $1.96, for a total transaction of $46,887.12. Following the completion of the transaction, the chief financial officer directly owned 252,688 shares of the company’s stock, valued at approximately $495,268.48. This trade represents a 8.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Matthew W. Foehr sold 30,843 shares of the company’s stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $1.71, for a total value of $52,741.53. Following the completion of the sale, the chief executive officer owned 4,403,277 shares of the company’s stock, valued at approximately $7,529,603.67. This trade represents a 0.70% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 130,021 shares of company stock valued at $233,398 over the last 90 days. 8.60% of the stock is currently owned by insiders.

Institutional Trading of OmniAb

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Private Management Group Inc. grew its position in OmniAb by 1.1% in the second quarter. Private Management Group Inc. now owns 2,558,045 shares of the company’s stock worth $4,451,000 after buying an additional 28,286 shares during the last quarter. Towerview LLC boosted its stake in shares of OmniAb by 43.3% during the 2nd quarter. Towerview LLC now owns 831,100 shares of the company’s stock worth $1,446,000 after acquiring an additional 251,100 shares in the last quarter. Isthmus Partners LLC grew its holdings in shares of OmniAb by 21.2% in the 2nd quarter. Isthmus Partners LLC now owns 568,043 shares of the company’s stock worth $988,000 after acquiring an additional 99,336 shares during the last quarter. Rhumbline Advisers lifted its holdings in shares of OmniAb by 6.0% during the second quarter. Rhumbline Advisers now owns 160,728 shares of the company’s stock valued at $280,000 after purchasing an additional 9,163 shares during the last quarter. Finally, Invesco Ltd. lifted its holdings in shares of OmniAb by 9.9% during the fourth quarter. Invesco Ltd. now owns 136,309 shares of the company’s stock valued at $252,000 after purchasing an additional 12,258 shares during the last quarter. 72.08% of the stock is owned by institutional investors and hedge funds.

About OmniAb

OmniAb, Inc (NASDAQ: OABI) operates as a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s integrated antibody discovery platform combines proprietary transgenic animal models, in vitro screening, and in silico engineering to accelerate lead identification and optimization. OmniAb offers both fee-for-service collaborations and license agreements, enabling biopharmaceutical partners to leverage its suite of technologies for programs spanning oncology, immunology, and other therapeutic areas.

Founded in 2016 and headquartered in Seattle, Washington, OmniAb went public in May 2021.